Ophthalmic compositions comprising F6H8
AssigneeNovaliq GmbH
InventorsBernhard Günther, Frank Löscher, Hartmut Voss, Sonja Krösser, Kirsten Eickhoff, Daniela Willen, Markus Beier, Thomas Schlüter
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.
Claims21
A method of providing delayed ophthalmic release of a semifluorinated alkane, wherein the method comprises the steps of (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF2)6(CH2)8H and 2-perfluorohexyloctane, wherein the amount is effective to enrich an ophthalmic tissue in F(CF2)6(CH2)8H, and (b) delayed release of F(CF2)6(CH2)8H from the enriched ophthalmic tissue;
- wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid drops;
- wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease);
- and wherein the patient is non-responsive to physical methods of treating Meibomian Gland Dysfunction.
A method of treating keratoconjunctivitis sicca (dry eye disease) due to Meibomian gland dysfunction, wherein the method comprises the steps of (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF2)6(CH2)8H and 2-perfluorohexyloctane, wherein the amount is effective to enrich an ophthalmic tissue in F(CF2)6(CH2)8H, and optionally (b) delayed release of F(CF2)6(CH2)8H from the enriched ophthalmic tissue;
- wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid drops;
- wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease);
- and
- wherein the patient is non-responsive to physical methods of treating Meibomian Gland Dysfunction.
A method of treating keratoconjunctivitis sicca (dry eye disease), wherein the method comprises the steps of (a) administering to the eye of a patient in need thereof an amount of an ophthalmic composition consisting of a mixture of F(CF2)6(CH2)8H and 2-perfluorohexyloctane, wherein the amount is effective to enrich an ophthalmic tissue in F(CF2)6(CH2)8H, and optionally (b) delayed release of F(CF2)6(CH2)8H from the enriched ophthalmic tissue;
- wherein the ophthalmic composition is administered to the surface of the cornea and/or the conjunctiva in the form of liquid drops;
- wherein the patient suffers from keratoconjunctivitis sicca (dry eye disease);
- and
- wherein the patient is non-responsive to physical methods of treating Meibomian Gland Dysfunction.
Dependencies are inferred from the claim text.